Zyprexa Willful Infringement Claim Dismissal Could Speed Ivax Launch

Ivax said it is more likely to launch its generic of the antipsychotic Zyprexa ahead of an appellate court decision now that Lilly has agreed to dismiss a willful infringement claim prior to trial

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet